Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
151
-
Total 13F shares, excl. options
-
19.6M
-
Shares change
-
-524K
-
Total reported value, excl. options
-
$1.02B
-
Value change
-
-$25.6M
-
Put/Call ratio
-
0.12
-
Number of buys
-
80
-
Number of sells
-
-61
-
Price
-
$51.87
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q3 2022
172 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q3 2022.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 151 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.6M shares
of 27.8M outstanding shares and own 70.55% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.62M shares), ARMISTICE CAPITAL, LLC (2.07M shares), FARALLON CAPITAL MANAGEMENT LLC (1.55M shares), VANGUARD GROUP INC (1.48M shares), STATE STREET CORP (1.38M shares), NORTHERN TRUST CORP (964K shares), RA CAPITAL MANAGEMENT, L.P. (897K shares), Krensavage Asset Management, LLC (589K shares), DIMENSIONAL FUND ADVISORS LP (510K shares), and Fairmount Funds Management LLC (469K shares).
This table shows the top 151 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.